Barcelona

• A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previo … Ended recruitment
  2024-511747-25-00 4 2019-12-23 B-cell non-Hodgkin lymphoma (NHL)
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study) Ended recruitment
  2022-502604-67-00 10 2019-12-20 Malignant pleural mesothelioma (MPM)
• Study of Biological Effect in Tumor Samples from Clinical Trial Patients Treated with Ds8201 Ended recruitment
  2023-508830-33-00 4 2019-12-13 Patients diagnosed with advanced or metastatic cancer treated with Tra
• Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cance … Ended recruitment
  2024-517705-93-00 9 2019-12-13 Histologically or cytologically confirmed diagnosis of extensive or li
• ADP-A2M4 in Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Ended recruitment
  2024-512847-21-00 4 2019-12-11 Advanced Synovial Sarcoma
• Study to evaluate the safety and efficacy of nivolumab combined with ipilimumab as first-line (1L) therapy for participants with advanced HC … Ended recruitment
  2023-508635-31-00 5 2019-12-03 Hepatocellular Carcinoma
• A study to determine whether the addition of Dostarlimab (TSR-042) delays recurrence of advanced endometrial cancer Ended recruitment
  2023-506551-23-00 5 2019-11-21 Recurrent or primary advanced (Stage III or IV) endometrial cancer
• A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and … Ended recruitment
  2024-510626-89-00 5 2019-11-18 Non-Alcoholic Steatohepatitis (NASH)
• Trimodality therapy with or without adjuvant Durvalumab to treat patients with bladder cancer Ended recruitment
  2024-512502-26-00 4 2019-11-06 Muscle-invasive bladder cancer
• A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive … Ended recruitment
  2023-507443-10-00 5 2019-11-04 Patients with somatostatin receptor positive, well-differentiated G2 a
• A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in pati … Ended recruitment
  2023-509463-24-01 4 2019-11-04 metastatic pancreatic cancer
• EORTC 1740: Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab ver … Ended recruitment
  2023-508853-13-00 4 2019-10-31 Oropharyngeal Squamous Cell Carcinoma
• Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatme … Ended recruitment
  2023-508841-42-00 3 2019-10-30 Different types of advanced cancer
• Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch … Ended recruitment
  2022-502354-14-00 5 2019-10-28 Completely resected Stage IIb/c melanoma
• Palbociclib for HR positive Isolated Local or Regional Recurrence of Breast Cancer Ended recruitment
  2024-510776-20-00 5 2019-10-25 Female or male patients with histologically confirmed HR-positive, HER
• A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged … Ended recruitment
  2023-507678-42-00 6 2019-10-24 Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Br
• This is a randomized, double-blind, controlled trial to evaluate the efficacy and safety of cabozantinib in combination with nivolumab and i … Ended recruitment
  2024-515616-47-00 5 2019-10-03 Metastatic Renal Cell Carcinoma
• Dose Escalation and Dose Expansion Study of PD1-LAG3 Bispecific Antibody in Patients with Advanced and/or Metastatic Solid Tumors Ended recruitment
  2023-503425-18-00 1 2019-10-02 Metastatic Solid Tumors
• GEN1042 Trial of Safety and Anti-tumor Activity in Subjects with Malignant Solid Tumors Ended recruitment
  2023-508526-10-00 7 2019-10-01 Malignant solid tumors: Patients with relapsed or refractory, advanced
• A Phase 3 clinical study to investigate the effects of BAN2401 in patients with Early Alzheimer's Disease. Ended recruitment
  2024-510887-22-00 5 2019-09-30 Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer
• A trial to learn if different cancer treatment combinations are safe and work in people with advanced non-small cell lung cancer that has mu … Ended recruitment
  2023-504624-25-00 4 2019-09-26 Advanced Non-Small Cell Lung Cancer
• A Phase 3, Randomized, Double-blind Study of Chemotherapy plus Nivolumab versus Chemotherapy plus Placebo provided before surgery, followed … Ended recruitment
  2022-502658-15-00 5 2019-09-22 Resectable Stage II-IIIB Non-small cell lung cancer
• A phase II trial of MK-3475 (pembrolizumab) in children and young adults with classical Hodgkin lymphoma Ended recruitment
  2023-504821-38-00 4 2019-09-19 Classical Hodgkin lymphoma in children and young adults

Showing 2,377–2,400 of 3,391 trials